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ABSTRACT 
This report reviews hepatitis A and B immunization recom- 
mendations and assesses the potential role of a combined 
hepatitis vaccine. Although hepatitis A and B are very different 
diseases, overlap exists in their epidemiologic patterns. Both 
are most prevalent in developing countries, with areas of low 
endemicity in industrialized nations. Potential sources of infec- 
tion common to both hepatitis A and hepatitis B (i.e., interna- 
tional travel, close contact with residents of institutions or young 
children and infants, male homosexual activity, and drug use) 
indicate that certain groups may be at increased risk of both 
diseases. Well-tolerated and immunogenic vaccines are avail- 
able for both hepatitis A and hepatitis B. Although hepatitis B 
vaccine is now being introduced into universal infant immu- 
nization programs in many countries, hepatitis A vaccination is 
currently recommended for high-risk groups only. This review 
examines the potential role of a single vaccination against both 
forms of hepatitis. 
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Hepatitis A and B pose serious public health concerns 
worldwide. Every year, approximately 1.4 million cases of 
hepatitis A are reported,l and worldwide, there are 
between 300 and 350 million chronic carriers of hepati- 
tis B.’ 
Hepatitis A virus (HAV) and hepatitis B virus (HBV) 
are very different: HAV is a small, nonenveloped RNA 
virus of the Picomaviridue family, whereas HBV is larger, 
with a DNA genome and lipid envelope.3-i Although 
modes of HAV and HBV transmission differ, considerable 
overlap exists between the populations that they affect. 
There has been a marked decline in the incidence of 
hepatitis A in industrialized countries, starting shortly 
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before World War II and becoming more rapid during the 
past 25 years, largely due to improved standards of living. 
As a result, levels of natural immunity to HAV infection 
are decreasing. Some groups remain at increased risk of 
infection because of their work or lifestyle. Similarly, rates 
of HBV infection are generally low in these countries, 
but high within certain at-risk groups. 
After hepatitis B vaccine became available, many 
countries adopted immunization strategies targeting high- 
risk groups. However, these strategies have two major 
limitations: (1) individuals at increased risk cannot always 
be identified before infection and (2) many reported cases 
of hepatitis cannot be related to identifiable risk factors. 
A routine, universal vaccination policy has been cited as 
a more effective means of control for hepatitis A and 
hepatitis B.“,’ 
In less developed countries, both forms of viral 
hepatitis remain highly endemic and present a serious 
health issue within these countries. Because of increasing 
international travel and the resulting exposure of non- 
immune individuals from countries where these viruses 
are less prevalent, distance is no longer a barrier to the 
spread of these diseases. 
TRANSMISSION 
Direct, person-to-person contact is the most important 
mode of HAYV transmission worldwide; it spreads rapidly 
within closed communities via the fecal-oral route.1,5,8 
Asymptomatic, infected infants and children who have 
not yet been toilet trained may pose particular risks to 
family or caregivers; in addition, frequent hand-to-mouth 
contact in these age groups also facilitates transmission 
through nurseries, schools, and daycare centers. In a vari- 
ant of the fecal-oral route, oral-anal contact between 
homosexuals is also a high-risk activity for hepatitis A.9 
Food or water contaminated with the virus may 
cause outbreaks of infection.1o-12 In a study addressing 
the survival of HAV in food and water, survival in samples 
of fresh, sea, and waste water, sediment, and various soils 
ranged from less than 0.1% to 3.2% after 84 days at 
25”C.‘3The same study demonstrated that more than 10% 
of HAV survived for 5 days in live oysters, and more than 
1% survived on contaminated confectionery maintained 
at 21°C for 1 month. 
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Hepatitis B virus can be present in almost any body 
fluid or secretion and can be transmitted via parenteral, 
percutaneous, or permucosal routes. Sexual transmission, 
during heterosexual and homosexual intercourse, is the 
major route of infection in industrialized countries, where 
it may account for over 50% of new cases.1*16 
Perinatal, vertical transmission from a carrier mother 
to her child usually occurs during delivery.Transmission 
rates of 70 to 90% have been reported in the offspring 
of hepatitis B e antigen (HBeAg) and serum HBV DNA 
positive women, with the lowest transmission rates found 
in the children of mothers with antibody to HBeAg (anti- 
HBe).17Js Before the introduction of vaccination programs 
in Southeast Asia, this type of transmission was respon- 
sible for up to 40% of chronic HBV carriers.19 In contrast, 
in the Middle East and Africa where there are also high 
rates of childhood hepatitis B and, hence, chronic infec- 
tion, horizontal transmission appears to be the principal 
pathway.20-22 
EPIDEMIOLOGY 
In general, hepatitis A and B are more endemic in devel- 
oping countries and less prevalent in industrialized coun- 
tries (Table 1) Improved socioeconomic conditions, safer 
water supplies, and better hygiene have markedly reduced 
HAV infection in an increasing number of countries. In 
Europe, for example, this trend was initially demonstrated 
in Germany,23 and currently, hepatitis A is no longer a 
common childhood infection in most European coun- 
tries.24 
As a result of the changing epidemiology of hepati- 
tis A, immunity to HAV is decreasing.The prevalence of 
anti-HAYV in children and young adults is falling, leaving 
generations susceptible to infection (Figure l).’ Because 
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Figure 1. Changes in HAV seroprevalence over 1 decade in two 
countries. (Reproduced with permissionl) 
the severity of hepatitis A is age-related, decreasing lev- 
els of naturally acquired immunity are complemented by 
an increase in outbreaks of overt hepatitis A among older 
children, adolescents, and young adults. Recent outbreaks 
in Italy and in Tarragona, Spain, suggest that this change 
is in progress. 25-27 A French study of school children 
reported that outbreaks often occurred at the start of the 
Table 1. Summary of Hepatitis A and Hepatitis B Endemicity 
Level to which Prevalence Chronic 
Disease is Endemic CW Carriers (%) Distribution Transmission 
Hepatitis A 
Hyperendemic 
(by age 5 Yr) 
High 
(by we 10 Yr) 
Intermediate 
(by we 25 YC 
Low 
(by age 50 vr) 
Hypoendemic 
(by age ~30 yr) 
90 
90 
90 
‘O-90 
<80 
- Africa, South America, Middle East, 
Southeast Asia 
Amazon Basin, Greenland, China, Person-to-person, community, school, 
Central America food, water 
- Southern and eastern Europe, former Person-to-person, community, school, 
Soviet Union, Middle East food, water, shellfish 
- North America, Australia, New Zealand, Person-to-person, community, school, 
Western Europe food, water, shellfish, daycare 
centers, hospital 
Northern Europe, Japan Person-to-person 
Hepatitis B 
High 
Intermediate 
Low 
>60 8-l 5 
20-60 2-7 
<20 <2 
Africa, Southeast Asia, South America Perinatal, person-to-person 
Southern and eastern Europe, former Perinatal or person-to-person in infancy 
Soviet Union, Middle East, Japan, 
South Asia, Central Asia, Central America 
North America, Australia, New Zealand, Sexual, parenteral 
northern and western Europe 
228 International Journal of Infectious Diseases / Volume 1, Number 4, April 1997 
school year, suggesting that children became infected 
with HAV while on vacation in areas where the virus is 
highly endemic and then passed the virus on to their fel- 
low pupilsz8The shift from asymptomatic infant infection 
to overt infection in older children and young adults may 
make the initiation of routine hepatitis A vaccination pro- 
grams more important in the future. 
Although HBV has infected more than ‘2 billion 
people worldwide, geographic areas may be categorized 
as high, intermediate, or low endemicity and the disease 
burden is greatest in the developing nationsz9”i Preva- 
lence is lowest in regions with the highest standards of 
living, including North America, Australasia, and northern 
and western Europe (see Table 1). In the United States, 
17,933 confirmed cases of hepatitis B were reported 
between 1990 and 1992.15 
Hepatitis is not homogeneously endemic throughout a 
region.Within areas of low prevalence, certain ethnic groups 
or isolated communities may show a higher level of 
endemicity than the rest of the population. For example, 
HAV and HBV are more prevalent among Eskimo com- 
munities than in the general population of Alaska, Green- 
land, and Canada.32-35 Similar patterns of increased 
hepatitis A or B endemicity in isolated communities 
within regions where the diseases are not highly endemic 
have been reported for the Navajo in New Mexico,36Aus- 
tralian aborigines,37-39 and the Maoris of New Zealand.*O 
STRATEGIES AND RECOMMENDATIONS FOR 
VACCINATION AGAINST HEPATITIS A AND B 
Vaccines against hepatitis B have been available since the 
early 1980s. Initial recommendations for vaccination in 
countries where the diseases are not highly endemic 
focused on groups considered to be at high risk of hepati- 
tis B infectionThese included infants of HBsAg-positive 
mothers, the occupationally exposed, homosexual men, 
heterosexuals with multiple partners, patients exposed 
to blood products, intravenous drug users, travellers, 
inmates and staff of institutions, and certain ethnic 
groups. 
Although this strategy offered personal protection of 
individuals in high-risk groups, it failed to control hepati- 
tis B in any country 41 In many countries, only one high- 
risk group accounts for 80 to 90% of vaccine uptake; that 
is, health care workers, who generally represent less than 
10% of cases. No country was able to target other impor- 
tant high-risk groups effectively, such as practicing male 
homosexuals, intravenous drug users, and prostitutes, 
because of problems with identification and education 
and awareness of the risks of hepatitis B.42,43 Further- 
more, even in countries where hepatitis B is not highly 
endemic, many cases occur in individuals not readily iden- 
tifiable as belonging to any high-risk group. Therefore, 
policy was revised to correspond with that for countries 
with high and intermediate levels of endemicity where 
universal infant vaccination was recommended. Currently, 
the World Health Organization (WHO) recommends inte- 
gration of hepatitis B vaccination into national childhood 
and adolescent immunization programs.’ By early 1996, 
80 countries had national or regional policies of routine 
infant or adolescent immunization in place.41 These 
include Italy, France, Spain, Portugal, the United States, 
Canada, and New Zealand, which have low levels of 
hepatitis B endemicity. 
Selective vaccination of high-risk groups still has a 
role to play, because infant or adolescent vaccination pro- 
grams do not reach older subjects. In addition, a Euro- 
pean Community directive now requires employers to 
offer hepatitis B vaccination, free of charge, to employees 
at risk from infection,** and in the United States, employ- 
ers can be fined for failing to protect employees against 
blood-borne pathogens. 
Hepatitis A vaccine became available in Europe in 
1991 and 1992 and has, more recently, been licensed in 
America. At present, the WHO identifies the following 
groups as being potentially at increased risk of hepatitis 
A infection’: 
. travellers to regions other than NorthAmerica,West- 
ern Europe, Japan, or Australasia, particularly for trips 
of long duration and for frequent travellers 
. daycare children and staff 
. individuals with chronic liver disease 
. individuals in residential institutions 
. homosexually active men 
. intravenous drug users 
. food handlers. 
In future these groups may be extended to include health 
care workers and sewage workers, after the risk of hepati- 
tis A infection for these individuals has been further 
assessed. 
The WHO suggests that effective control in popula- 
tions with high and intermediate levels of hepatitis A 
endemicity will be achieved by routine, universal immu- 
nization.6 Because hepatitis A is an acute disease and 
humans are the only natural reservoir, once high levels of 
immunity are achieved and maintained within a popula- 
tion, the virus cannot re-enter. Increased awareness of 
the effects of shifting epidemiology may lead to incor- 
poration of routine immunization into national programs 
in areas where disease is less prevalent. 
INITIAL PRIORITY GROUPS 
FOR COMBINED VACCINATION 
Adolescents and Young Adults 
In areas with low endemicity, most children are not 
exposed to viral hepatitis at home or in school. As they 
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grow up and their horizons expand, however, they begin 
to travel, take up employment, and become sexually 
active, and the risk of exposure to one, or both viruses 
significantly increases. Therefore, routine vaccination of 
infants or adolescents is the most effective way to control 
hepatitis A and B. 
The rationale for routine hepatitis B vaccination is 
well established, and by 1997, all countries should have 
programs of infant or early adolescent vaccination in 
place.’ In the short term, however, there will be adoles- 
cents and young adults who will miss out on routine vac- 
cination, thus remaining at increased risk of HBV infection 
and requiring catch-up vaccination. 
As most adolescents and young adults will not have 
been exposed to HAV during childhood, these same gen- 
erations are now susceptible to HAV infection. Rather 
than the mild or asymptomatic infection characteristic 
of infant infection, hepatitis A in older generations is overt 
and potentially severe. Mortality is age-related, increasing 
from 0.3% for those 15 to 39 years of age to 2.1% for 
those over 40 years of age.45 
Travellers and Expatriate Workers 
Viral hepatitis is one of the most common illnesses to 
afflict travellers. Hepatitis A is the most frequently occur- 
ring vaccine-preventable disease in travellers from indus- 
trialized countries visiting developing countries.*” For 
unprotected travellers in good-quality accommodation, it 
is estimated that the incidence of hepatitis A is 3 to 6 per 
1000 per month of stay in a developing country*’ Among 
backpackers and other travellers who eat from street mar- 
kets, or in unhygienic conditions, the incidence increases 
to 20 per 1000 per month; this includes many younger 
travellers.*’ Among expatriates working in developing 
countries, an incidence of 0.8 to 2.4 symptomatic or 
asymptomatic HBV infections can be expected per 1000 
per month.*’ Risk factors for HBV infection in travellers 
to areas where disease is highly endemic include unpro- 
tected sex, surgical or dental procedures, and contami- 
nated needles and syringes used to administer medication. 
Several categories of travellers and expatriate work- 
ers at risk from hepatitis A or hepatitis B were identified 
by Lange in 1987.*’ Military personnel serving overseas 
represent a readily identifiable category at high risk of 
both hepatitis A and hepatitis B infection.49-51 Many mili- 
tary personnel are young men in the age range least likely 
to have acquired natural immunity.They may be exposed 
to poor living conditions in the field, and may indulge in 
high-risk sexual activity, making immunization a priority 
for military commands that do not want to have their 
forces depleted by illness.49-51 Missionaries and aid work- 
ers are also at high risk. For example, in a study of 360 
American missionaries in sub-Saharan Africa between 
1967 and 1984,16% had anti-HAV and 3% anti-HBs before 
their mission; at the end of their service, seroprevalence 
Table 2. Summary of Those at Dual Risk of infection with 
Hepatitis A and B in Developing Countries 
l Military personnel 
l Foreign service personnel 
l Missionaries and aid workers 
l Health care personnel 
l Travellers spending prolonged periods in Asia, Africa, the Middle 
East, or the Far East 
l Persons whose activities or life-style places them at risk 
rates were 42% and 26%, respectively.52 Travellers and 
expatriate workers who may benefit from combined 
hepatitis A and B vaccination are summarized in Table 2. 
Men Who Have Sex with Men 
In the United States, between 1980 and 1985, 20% of 
hepatitis B cases resulted from homosexual activity. l6 The 
risk from anal intercourse is considered particularly high 
and is further increased by intercourse with multiple 
partners. However, since the emergence of human 
immunodeficiency virus (HIV) and acquired immuno- 
deficiency syndrome (AIDS), changes in sexual practices 
(“safer sex”) have led to a dramatic decline in the num- 
ber of cases of hepatitis B among male homosexuals; by 
1992 homosexual activity accounted for only 8.4% of 
cases in the United States.‘j 
Extensive outbreaks of hepatitis A have been 
reported among homosexual men in urban areas in the 
United States, Canada, and Australia.j3-56 Transmission 
within the homosexual and bisexual communities is most 
likely to be via oral-anal contact. 
Men who have sex with men are candidates for vac- 
cination against hepatitis A,’ and despite the reduction in 
the incidence of hepatitis B since the mid-1980s they 
should still be recommended for hepatitis B vaccination. 
Increased health awareness has made male homosexuals 
one of the groups most likely to seek health advice; there- 
fore, homosexual and bisexual men should be educated 
about the risks of hepatitis A and B and, thus, prompted 
to seek vaccination. 
Drug Users 
Intravenous drug users in industrialized countries are rou- 
tinely exposed to blood that has not been screened for 
viral pathogens, through sharing unsterilized needles. Fur- 
thermore, they are unlikely to be receptive to health 
advice or to seek vaccination. Over the past 10 years, 
hepatitis A outbreaks among intravenous drug users have 
been reported in Europe and the United States5’,j8; hepati- 
tis B has long been recognized as a risk to this group. 16,59 
In the United States, between 1990 and 1992,13 to 17% 
of the reported cases of hepatitis B were attributed to 
intravenous drug use,15 and in Sweden, between 1986 
and 1990,42.6% of cases of hepatitis B occurred in drug 
users.6o Hepatitis A acquired by intravenous drug use 
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accounted for 2.8 to 5.9% of cases in the United States 
between 1990 and 1992.15 
The prevalence of serologic markers for viral hepati- 
tis among intravenous drug users is far higher than among 
the population at 1arge.A Danish study found that mark- 
ers of hepatitis A infection were four times higher in intra- 
venous drug users than in the general population, and 
the prevalence of markers for hepatitis B infection were 
30 times higher.61 In addition to needle sharing, other 
typical aspects of the drug user’s life-style, such as poor 
living conditions, may contribute to the risk of viral 
hepatitis. 
Health Care Workers 
Hepatitis B is among the most common occupational haz- 
ards for health care workers.@ Although the most fre- 
quent method of transmission is through needlestick 
injury with contaminated (HBsAg-positive) blood, most 
other body fluids are potentially infectious, including 
semen, vaginal secretions, cerebrospinal fluid, saliva, and 
even tears.63,64 It is estimated that 502 health care work- 
ers in northern Europe and 6423 in southern Europe con- 
tract hepatitis B each year. 65 Cleaning and support staff 
are to be counted among the highest risk groups, fol- 
lowed by nursing staff, technical support staff, physicians, 
and surgeons.@ 
Since the introduction of hepatitis B vaccine, rec- 
ommendations for its use by health care personnel have 
brought about the highest uptake rate of vaccination by 
any of the identifiable risk groups. In Europe, hepatitis B 
vaccination coverage is 40 to 60% for medical and den- 
tal workers.66 
A German study has suggested that the risk of con- 
tracting hepatitis A is two to three times greater for nurs- 
ing staff than for the general population, including doctors 
or dentists.67 Furthermore, pediatricians have been found 
to have a greater prevalence of markers for hepatitis A 
than other specialists. 62 Exposure to the feces of infants 
with asymptomatic infections appears to be the impor- 
tant risk factor for pediatriciansAlso, outbreaks of hepati- 
tis A have been reported among nursing staff dealing with 
fecally incontinent adult patients.68 
Despite the relatively low incidence of hepatitis A 
outbreaks among health care workers, vaccination of 
those personnel at highest risk (e.g., laboratory techni- 
cians and those dealing with pediatric patients) may be 
appropriate. However, it should be borne in mind that 
staff often move from low-risk to high-risk wards, par- 
ticularly young employees who may still be training. It 
may, therefore, be appropriate to vaccinate student 
nurses, medical students, and those training in the allied 
professions while they are still at this stage of their career. 
Young employees are more inclined to accept vaccina- 
tion, and vaccination programs are easier to implement 
within training environments. Health care workers from 
countries with low endemicity who undertake voluntary 
work in the developing world are at increased risk from 
both hepatitis A and hepatitis B infection and routine vac- 
cination for both forms of hepatitis is advisable. 
Staff and residents of large institutions are potentially 
at risk from both forms of hepatitis. In homes for the 
mentally handicapped, for example, there is close, regu- 
lar contact between individuals. Hepatitis B infection may 
spread from a chronically infected resident, via apparent 
and inapparent percutaneous transmission, to other res- 
idents and staff. Studies in Belgium have found a signifi- 
cantly higher prevalence of serologic markers for hepatitis 
B among the residents of homes for the mentally handi- 
capped than among the general population and, in addi- 
tion, evidence of horizontal transmission to relatives of 
hepatitis B carriers.69z70 
Outbreaks of hepatitis A in centers for the mentally 
handicapped have occurred in the past. Currently, how- 
ever, outbreaks occur less frequently; controlled studies 
are required to assess the current risk from hepatitis A 
among residents and staff. Whereas hepatitis A vaccine 
may have a role in protecting long-term residents and 
staff against outbreaks, close proximity and routine con- 
tact in residential institutions make hepatitis B vaccina- 
tion of residents and staff advisable as well. Inmates and 
staff in prisons and other closely confined groups, such 
as army bases or naval vessels are, likewise, at risk from 
both forms of viral hepatitis, and vaccination should be 
recommended. As in other risk groups, combined vacci- 
nation against both hepatitis A and hepatitis B could pro- 
duce considerable benefits, in terms of convenience, 
compliance, and acceptability to recipients. 
UNIVERSAL IMMUNIZATION AGAINST 
HEPATITIS A AND HEPATITIS B 
Universal infant and adolescent immunization strategies 
for hepatitis B should, in the future, produce widespread 
immunity to this disease. Few countries, however, have 
catch-up or adult vaccination programs other than for 
health care workers, leaving, in the midterm, groups of 
individuals at risk from infection. Although routine immu- 
nization against hepatitis A will not be initiated in the 
immediate future, improved environmental and socio- 
economic conditions have already produced a dramatic 
decrease in the incidence of this disease, leaving signifi- 
cant numbers of people without naturally acquired immu- 
nity. Although this changing epidemiology may appear 
encouraging, the effect is to render generations suscep- 
tible to hepatitis A infection, with a subsequent increase 
in community-wide outbreaks and more serious illness. 
Targeted immunization of at-risk individuals may con- 
trol hepatitis A in the short term. However, the nature of 
the disease offers potentially exciting opportunities for a 
preventive approach in regions of low endemicity, which 
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could be achieved by routine vaccination. By reducing 
the number of injections required to produce protection 
and cutting the cost of vaccine, a combined hepatitis A 
and B vaccine would be more acceptable to recipients, 
parents, and physicians, and compliance would probably 
improve. Indirect savings could be achieved by saving 
physicians’ and nurses’ time, cutting administration costs 
and by reducing time off work for recipients. 
CONCLUSION 
Hepatitis A and hepatitis B remain serious public health 
concerns worldwide. Well tolerated and immunogenic 
vaccines exist for both infections, with the hepatitis B 
vaccine currently being introduced into large-scale immu- 
nization programs in 80 countries.41 However, because 
hepatitis A is often not considered a clinically severe con- 
dition, the inclusion of hepatitis A vaccine into routine 
immunization programs is not currently a priority. 
Some groups identified as being at increased risk of 
hepatitis B are also at increased risk of contracting hepati- 
tis A. A combined vaccine against hepatitis A and hepati- 
tis B could offer advantages in terms of reducing the 
number of injections required, improving acceptability 
to the recipient, and increasing compliance. Ultimately, the 
use of hepatitis A and hepatitis B vaccines, either sepa- 
rately or as a combined vaccine, will depend upon a com- 
bination of the local epidemiology, disease burden, 
economic considerations with respect to vaccine cost, 
the health care priorities of local medical authorities, and 
vaccination policies. 
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